NSE · STAR
Strides Pharma Science Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹660 Cr with net profit ₹9 Cr — a 1.4% net margin, versus 12.52% the period before.
Shareholding
As of 2026-09-30
- Promoter29%
- Public27.51%
- FII27.98%
- DII15.51%
93,336 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.64× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #29 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Strides Pharma Science Ltd.(this company) | ₹9,214 Cr | 16.04 | 2.7 | 18.05% | 11.83% |
AI analysis
AI-generated · google/gemini-2.5-flashStrides Pharma Science Ltd. (STAR) operates in the Pharmaceuticals sector, with a market capitalization of Rs 9690 Cr. The company reported a revenue growth of 17.36% and a profit margin of 11.45%.
Positives
- +Revenue grew 17.36%.
- +Return on Equity (ROE) is 17.9%.
- +Return on Capital Employed (ROCE) is 17.30%.
Negatives
- −Promoter pledge percentage is 27.27%, which indicates a notable portion of promoter shares are pledged.
- −The profit margin is 11.45%, indicating the company's profitability per unit of revenue.
- −The trailing price-to-earnings ratio is 76.35.
Financial Performance
Strides Pharma Science Ltd. reported quarterly revenues reaching Rs 1323.47 Cr in Mar 2026, marking an increase from Rs 1194.65 Cr in Dec 2025. Net profit also rose to Rs 126.94 Cr in Mar 2026, up from Rs 202.11 Cr in Dec 2025. The company's EBITDA increased from Rs 292.18 Cr in Dec 2025 to Rs 194.59 Cr in Mar 2026.
Profitability & Returns
The company recorded a Return on Equity (ROE) of 17.9% and a Return on Capital Employed (ROCE) of 17.30%. The profit margin for the company stands at 11.45%. The Earnings Per Share (EPS) is Rs 62.84.
Balance Sheet
Strides Pharma Science Ltd. has a debt-to-equity ratio of 0.94. The book value per share is Rs 337.15.
Ownership & Pledges
As of March 31, 2026, promoter holding in Strides Pharma Science Ltd. was 27.91%. FIIs held 28.68% and DIIs held 14.45%. The public shareholding was 28.96%. A significant portion of promoter shares, 27.27%, are pledged.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Strides Pharma Science Ltd.share price & fundamentals